SHPH vs. CDIO, BFRI, AEZS, PRTG, CPHI, FRTX, SNPX, ALBT, KTTA, and APM
Should you be buying Shuttle Pharmaceuticals stock or one of its competitors? The main competitors of Shuttle Pharmaceuticals include Cardio Diagnostics (CDIO), Biofrontera (BFRI), Aeterna Zentaris (AEZS), Portage Biotech (PRTG), China Pharma (CPHI), Fresh Tracks Therapeutics (FRTX), Synaptogenix (SNPX), Avalon GloboCare (ALBT), Pasithea Therapeutics (KTTA), and Aptorum Group (APM). These companies are all part of the "pharmaceutical products" industry.
Shuttle Pharmaceuticals vs. Its Competitors
Shuttle Pharmaceuticals (NASDAQ:SHPH) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
In the previous week, Shuttle Pharmaceuticals had 4 more articles in the media than Cardio Diagnostics. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 2 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.94 beat Shuttle Pharmaceuticals' score of 0.42 indicating that Cardio Diagnostics is being referred to more favorably in the news media.
4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by company insiders. Comparatively, 22.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cardio Diagnostics has higher revenue and earnings than Shuttle Pharmaceuticals.
Shuttle Pharmaceuticals has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -28,539.39%. Cardio Diagnostics' return on equity of -84.55% beat Shuttle Pharmaceuticals' return on equity.
Shuttle Pharmaceuticals has a beta of -1.09, indicating that its share price is 209% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.97, indicating that its share price is 197% more volatile than the S&P 500.
Cardio Diagnostics has a consensus target price of $60.00, indicating a potential upside of 1,562.05%. Given Cardio Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than Shuttle Pharmaceuticals.
Summary
Cardio Diagnostics beats Shuttle Pharmaceuticals on 11 of the 13 factors compared between the two stocks.
Get Shuttle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SHPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shuttle Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SHPH) was last updated on 7/2/2025 by MarketBeat.com Staff
Free SHPH Stock Alerts